Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Queensland Health
Citi
Daiichi Sankyo
Mallinckrodt
Covington
Harvard Business School
AstraZeneca
UBS
Chinese Patent Office

Generated: August 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Composition
Abstract:There is described a composition comprising a substantially clear, sterile aqueous solution containing as active ingredient a therapeutically useful proportion of 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof, or 5,5'-[[5,5'-(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-yl]]t etrazole, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof. The composition is indicated for the treatment of conditions of the eye and the nose.
Inventor(s): Stevenson; Neil Arthur (Loughborough, EN), Wardell; George (Loughborough, EN)
Assignee: Fisons Limited (London, EN)
Application Number:05/471,141
Patent Claims: 1. In a pharmaceutical composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, the improvement according to which the said active ingredient is present in an amount of from 0.1 to 10% w/v, the said composition contains less than about 0.40 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the said composition being a substantially clear, sterile aqueous solution.

2. A composition according to claim 1 which additionally contains from 0.001 to 0.10% w/v of a pharmaceutically acceptable preservative, said composition being made up by mixing an aqueous solution containing the 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically effective salt thereof with an aqueous solution containing the preservative and subjecting the thus obtained admixture to filtration.

3. A composition according to claim 2 containing from 0.001 to 0.5% w/v of sodium 2-(ethyl mercuriothio)benzoate.

4. A composition according to claim 2 wherein the preservative is a member selected from the group of compounds of the formula ##SPC2##

wherein R is alkyl C.sub.8 H.sub.17 to C.sub.18 H.sub.37, and a mixture of such compounds.

5. A composition according to claim 4 containing from 0.005 to 0.10% w/v of the preservative.

6. In a pharmaceutical composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, the improvement according to which the said active ingredient is present in an amount of from 0.1 to 10% w/v, the composition contains less than about 20 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the composition contains from about 0.05 to 0.1% w/v of a pharmaceutically acceptable chelating or sequestering agent, and the said composition being a substantially clear aqueous solution.

7. A composition according to claim 6 wherein the chelating or sequestering agent is ethylene diamine tetraacetic acid or a salt thereof.

8. A composition according to claim 6 which additionally contains from 0.001 to 0.10% w/v of a pharmaceutically acceptable preservative, said composition being made up by mixing an aqueous solution containing the 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof and the chelating or sequestering agent with an aqueous solution containing the preservative and subjecting the thus obtained admixture to filtration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
UBS
McKesson
Colorcon
Deloitte
Express Scripts
Moodys
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot